Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board
News Feb 14, 2013
Nanobiotix has announced that Dr. Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun in their roles, as part of a planned Supervisory Board succession.
Dr. Herrera joins Nanobiotix Supervisory Board with more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing.
Before setting up his own oncology consultancy - Alain Oncologie Consulting (AOC) -, he headed the Oncology business at Sanofi-Aventis for ten years, where he was Vice President for the Global Oncology Business Strategy and Development (2007-2008) and Head of the Global Oncology Franchise (1998-2007).
He contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®).
His previous responsibilities within the pharmaceutical industry included the roles of Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc).
In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.
Dr. Herrera said: “Over recent years, Nanobiotix’s nanomedicine technology has repeatedly demonstrated its significant potential for optimizing the efficacy of radiotherapy, a treatment currently used for about 60% of cancer patients and a key component of the treatment strategy in curative setting. I'm both delighted and privileged to be able to play a part in helping Nanobiotix to deliver its objectives and to overcome the challenges that lie ahead. I look forward to working with the Nanobiotix team.”
“We welcome Dr. Alain Herrera to the Supervisory Board. Pioneer of industrial oncology, his business and pharmaceutical industry experience will add important expertise to the Board,” said Laurent Levy, CEO of Nanobiotix.
Levy continued, “Alain has been a member of the Scientific Advisory Board of Nanobiotix over the past years, so he already has a thorough knowledge of its business and its technology. We believe his skills and oncology leadership will assist us in fulfilling our strategic business objectives and to progress our international development.”
Laurent Levy added: "I would also like to thank Thierry Chopin and Isabelle Bou Antoun for the contribution they have made over the last years of service, helping to position Nanobiotix for a promising future."
The nomination of Dr. Herrera will be submitted to the approval of the next general shareholders’ meeting in accordance with applicable law.